Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies

Molecular Metabolism

Volumn 3, Issue 3, 2014, Pages 275-283

  Coppieters, Ken T ^a   Von Herrath, Matthias G ^a,b  

^a NOVO NORDISK INC   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Antigenic immunotherapies; Atherosclerosis; Macrophages; Metabolic syndrome; Obesity; T cells; Type 1 diabetes; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B100; AUTOANTIGEN; C PEPTIDE; CD3 ANTIBODY; CHAPERONIN 60; CHROMOGRANIN; DIAMYD; DIAPEP277; DNA VACCINE; HEAT SHOCK PROTEIN 65; IMMUNOLOGICAL ADJUVANT; INSULIN; NANOPARTICLE; PLASMID DNA; PROINSULIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ANTIGEN SPECIFICITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 84896949861     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.12.005     Document Type: Review

References (86)

1. Coppieters K., von Herrath M., Homann D. Autoimmunity and autoimmune diseases. Fundamental immunology 2013, 1069-1112. Lippinkott Williams and Wilkins, Philadelphia. W. Paul (Ed.).
2. Coppieters K., von Herrath M. Animal models of organ-specific autoimmune disease. The autoimmune diseases 2014, Elsevier, Oxford. I. Mackay, N. Rose (Eds.).
3. Coppieters K.T., Sehested H.B., von Herrath M.G. Clinical potential of antigen-specific therapies in type 1 diabetes. Review of Diabetic Studies 2012, 9:328-337.
4. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunological reviews 2011, 241:241-259.
5. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. Journal of Clinical Investigation 2011, 121:2111-2117.
6. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nature Reviews Cardiology 2009, 6:399-409.
7. Van Belle T.L., Coppieters K.T., von Herrath M.G. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological Reviews 2011, 91:79-118.
8. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., Yu L., Wegmann D.R., Hutton J.C., Elliott J.F., Eisenbarth G.S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
9. Di Lorenzo T.P., Peakman M., Roep B.O. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clinical and Experimental Immunology 2007, 148:1-16.
10. Velthuis J.H., Unger W.W., Abreu J.R., Duinkerken G., Franken K., Peakman M., Bakker A.H., Reker-Hadrup S., Keymeulen B., Drijfhout J.W., Schumacher T.N., Roep B.O. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
11. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., Atkinson M.A., Roep B.O., von Herrath M.G. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. Journal of Experimental Medicine 2012, 209:51-60.
12. Assan R., Feutren G., Debray-Sachs M., Quiniou-Debrie M.C., Laborie C., Thomas G., Chatenoud L., Bach J.F. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1985, 1:67-71.
13. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., Madeira M.I., Malmegrim K.C., Foss-Freitas M.C., Simoes B.P., Martinez E.Z., Foss M.C., Burt R.K., Voltarelli J.C. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Journal of the American Medical Association 2009, 301:1573-1579.
14. Ross L.F., Philipson L.H. Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus. Journal of the American Medical Association 2007, 298:285-286.
15. Feldt-Rasmussen B., Jensen T., Dieperink H., Mandrup-Poulsen T., Nerup J., Bendtzen K., Andersen V., Kemp E., Leyssac P.P. Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus,. Diabetic Medicine 1990, 7:429-433.
16. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., Lakey J.R., Shapiro A.M. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
17. Coppieters, K.T., Harrison, L.C., von Herrath, M.G., 2013. Trials in type 1 diabetes: antigen-specific therapies. Clinical Immunology 149(3):345-355. [Epub 2013 Feb 15. Review. PMID:23490422]. http://dx.doi.org/10.1016/j.clim.2013.02.002.
18. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:123-127.
19. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., von H.M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. Journal of Clinical Investigation 2006, 116:1371-1381.
20. von H.M. Combination therapies for type 1 diabetes: why not now?. Immunotherapy 2010, 2:289-291.
21. Sarikonda, G., Pettus, J., Phatak, S., Sachithanantham, S., Miller, J.F., Wesley, J.D., Cadag, E., Chae, J., Ganesan, L., Mallios, R., Edelman, S., Peters, B., von Herrathe, M.J., 2013. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. Autoimmunity. pii:S0896-8411(13)00150-9. [Epub ahead of print. PMID:24387802]. http://dx.doi.org/10.1016/j.jaut.2013.12.003.
22. Wells, H.G., 1911. Studies on the chemistry of anaphylaxis (III). Experiments with isolated proteins, especially those of the hen's egg. The Journal of Infectious Diseases 9, 147-171.
23. Burks A.W., Jones S.M., Wood R.A., Fleischer D.M., Sicherer S.H., Lindblad R.W., Stablein D., Henning A.K., Vickery B.P., Liu A.H., Scurlock A.M., Shreffler W.G., Plaut M., Sampson H.A. Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine 2012, 367:233-243.
24. Varshney P., Jones S.M., Scurlock A.M., Perry T.T., Kemper A., Steele P., Hiegel A., Kamilaris J., Carlisle S., Yue X., Kulis M., Pons L., Vickery B., Burks A.W. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. Journal of Allergy and Clinical Immunology 2011, 127:654-660.
25. Zhang Z.J., Davidson L., Eisenbarth G., Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:10252-10256.
26. Bitar D.M., Whitacre C.C. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cellular Immunology 1988, 112:364-370.
27. Nagler-Anderson C., Bober L.A., Robinson M.E., Siskind G.W., Thorbecke G.J. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:7443-7446.
28. Petersen J.S., Bregenholt S., Apostolopolous V., Homann D., Wolfe T., Hughes A., De J.K., Wang M., Dyrberg T., von Herrath M.G. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clinical and Experimental Immunology 2003, 134:38-45.
29. von Herrath M.G., Dyrberg T., Oldstone M.B. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. Journal of Clinical Investigation 1996, 98:1324-1331.
30. Quinn, S., 2001. Human trials scientists, investors, and patients in the quest for a cure.
31. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., Cuthbertson D., Rafkin-Mervis L.E., Chase H.P., Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial - type 1. Diabetes Care 2005, 28:1068-1076.
32. Harrison L.C., Dempsey-Collier M., Kramer D.R., Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes,. Journal of Experimental Medicine 1996, 184:2167-2174.
33. Mamchak A.A., Manenkova Y., Leconet W., Zheng Y., Chan J.R., Stokes C.L., Shoda L.K., von H.M., Bresson D. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes 2012, 61:1490-1499.
34. Meiler F., Zumkehr J., Klunker S., Ruckert B., Akdis C.A., Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. Journal of Experimental Medicine 2008, 205:2887-2898.
35. Schloot N.C., Cohen I.R. DiaPep277(R) and immune intervention for treatment of type 1 diabetes. Clinical Immunology 2013, 149:307-316.
36. Ludvigsson J., Krisky D., Casas R., Battelino T., Castano L., Greening J., Kordonouri O., Otonkoski T., Pozzilli P., Robert J.J., Veeze H.J., Palmer J., Samuelsson U., Elding L.H., Aman J., Kardell G., Neiderud H.J., Lundstrom G., Albinsson E., Carlsson A., Nordvall M., Fors H., Arvidsson C.G., Edvardson S., Hanas R., Larsson K., Rathsman B., Forsgren H., Desaix H., Forsander G., Nilsson N.O., Akesson C.G., Keskinen P., Veijola R., Talvitie T., Raile K., Kapellen T., Burger W., Neu A., Engelsberger I., Heidtmann B., Bechtold S., Leslie D., Chiarelli F., Cicognani A., Chiumello G., Cerutti F., Zuccotti G.V., Gomez G.A., Rica I., Barrio R., Clemente M., Lopez Garcia M.J., Rodriguez M., Gonzalez I., Lopez J.P., Oyarzabal M., Reeser H.M., Nuboer R., Stouthart P., Bratina N., Bratanic N., de K.M., Weill J., Ser N., Barat P., Bertrand A.M., Carel J.C., Reynaud R., Coutant R., Baron S. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. New England Journal of Medicine 2012, 366:433-442.
37. Wherrett D.K., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Herold K.C., Marks J.B., Monzavi R., Moran A., Orban T., Palmer J.P., Raskin P., Rodriguez H., Schatz D., Wilson D.M., Krischer J.P., Skyler J.S. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327.
38. Diabetes Prevention Trial--Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. New England Journal of Medicine 346:1685-1691.
39. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
40. Coon B., An L.L., Whitton J.L., von Herrath M.G. DNA immunization to prevent autoimmune diabetes. Journal of Clinical Investigation 1999, 104:189-194.
41. Garren H., Robinson W.H., Krasulova E., Havrdova E., Nadj C., Selmaj K., Losy J., Nadj I., Radue E.W., Kidd B.A., Gianettoni J., Tersini K., Utz P.J., Valone F., Steinman L. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Annals of Neurology 2008, 63:611-620.
42. Roep B.O., Solvason N., Gottlieb P.A., Abreu J.R., Harrison L.C., Eisenbarth G.S., Yu L., Leviten M., Hagopian W.A., Buse J.B., von H.M., Quan J., King R.S., Robinson W.H., Utz P.J., Garren H., Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes. Science Translational Medicine 2013, 5:191ra82.
43. Miller S.D., Wetzig R.P., Claman H.N. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. Journal of Experimental Medicine 1979, 149:758-773.
44. Lutterotti A., Yousef S., Sputtek A., Sturner K.H., Stellmann J.P., Breiden P., Reinhardt S., Schulze C., Bester M., Heesen C., Schippling S., Miller S.D., Sospedra M., Martin R. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Science Translational Medicine 2013, 5:188ra75.
45. Getts D.R., Martin A.J., McCarthy D.P., Terry R.L., Hunter Z.N., Yap W.T., Getts M.T., Pleiss M., Luo X., King N.J., Shea L.D., Miller S.D. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nature Biotechnology 2012, 30:1217-1224.
46. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., Chawla A., Locksley R.M. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
47. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 2006, 116:3015-3025.
48. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., Ravussin E., Stephens J.M., Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,. Nature Medicine 2011, 17:179-188.
49. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., Sitaraman S.V., Knight R., Ley R.E., Gewirtz A.T. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
50. Ehses J.A., Perren A., Eppler E., Ribaux P., Pospisilik J.A., Maor-Cahn R., Gueripel X., Ellingsgaard H., Schneider M.K., Biollaz G., Fontana A., Reinecke M., Homo-Delarche F., Donath M.Y. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007, 56:2356-2370.
51. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine 2007, 356:1517-1526.
52. Kintscher U., Hartge M., Hess K., Foryst-Ludwig A., Clemenz M., Wabitsch M., Fischer-Posovszky P., Barth T.F., Dragun D., Skurk T., Hauner H., Bluher M., Unger T., Wolf A.M., Knippschild U., Hombach V., Marx N. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1304-1310.
53. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., Otsu M., Hara K., Ueki K., Sugiura S., Yoshimura K., Kadowaki T., Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine 2009, 15:914-920.
54. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A.B., Benoist C., Shoelson S., Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters,. Nature Medicine 2009, 15:930-939.
55. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., Dorfman R., Wang Y., Zielenski J., Mastronardi F., Maezawa Y., Drucker D.J., Engleman E., Winer D., Dosch H.M. Normalization of obesity-associated insulin resistance through immunotherapy. Nature Medicine 2009, 15:921-929.
56. Morris D.L., Cho K.W., Delproposto J.L., Oatmen K.E., Geletka L.M., Martinez-Santibanez G., Singer K., Lumeng C.N. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes 2013, 62:2762-2772.
57. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., Tsui H., Wu P., Davidson M.G., Alonso M.N., Leong H.X., Glassford A., Caimol M., Kenkel J.A., Tedder T.F., McLaughlin T., Miklos D.B., Dosch H.M., Engleman E.G. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nature Medicine 2011, 17:610-617.
58. Deng T., Lyon C.J., Minze L.J., Lin J., Zou J., Liu J.Z., Ren Y., Yin Z., Hamilton D.J., Reardon P.R., Sherman V., Wang H.Y., Phillips K.J., Webb P., Wong S.T., Wang R.F., Hsueh W.A. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metabolism 2013, 17:411-422.
59. Mito N., Kaburagi T., Yoshino H., Imai A., Sato K. Oral-tolerance induction in diet-induced obese mice. Life Sciences 2006, 79:1056-1061.
60. Wang Y., Li J., Tang L., Wang Y., Charnigo R., de V.W., Eckhardt E. T-lymphocyte responses to intestinally absorbed antigens can contribute to adipose tissue inflammation and glucose intolerance during high fat feeding. PLoS One 2010, 5:e13951.
61. Vaughan, K., Peters, B., Mallone, R., von Herrath, M., Roep, B.O., et al., 2013. Navigating diabetes-related immune epitope data: re-sources and tools provided by the Immune Epitope Database (IEDB). Immunome Research 9:063. http://dx.doi.org/10.4172/1745-7580.1000063.
62. Hondowicz B.D., Schwedhelm K.V., Kas A., Tasch M.A., Rawlings C., Ramchurren N., McIntosh M., D'Amico L.A., Sanda S., Standifer N.E., Shendure J., Stone B. Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One 2012, 7:e29949.
63. Adachi J., Kumar C., Zhang Y., Mann M. In-depth analysis of the adipocyte proteome by mass spectrometry and bioinformatics. Molecular and Cellular Proteomics 2007, 6:1257-1273.
64. Paul S., Kolla R.V., Sidney J., Weiskopf D., Fleri W., Kim Y., Peters B., Sette A. Evaluating the immunogenicity of protein drugs by applying MHC binding data and the immune epitope database and analysis resource. Clinical and Developmental Immunology 2013, 2013:467852.
65. Tse, K., Gonen, A., Sidney, J., Ouyang, H., Witztum, J.L., Sette, A., Tse, H., Ley, K., 2013. Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100. Frontiers in Immunology 4:493. [eCollection 2013. PMID:24416033 [PubMed]]. http://dx.doi.org/10.3389/fimmu.2013.00493.
66. Schipper H.S., Rakhshandehroo M., van de Graaf S.F., Venken K., Koppen A., Stienstra R., Prop S., Meerding J., Hamers N., Besra G., Boon L., Nieuwenhuis E.E., Elewaut D., Prakken B., Kersten S., Boes M., Kalkhoven E. Natural killer T cells in adipose tissue prevent insulin resistance. Journal of Clinical Investigation 2012, 122:3343-3354.
67. Lynch L., Nowak M., Varghese B., Clark J., Hogan A.E., Toxavidis V., Balk S.P., O'Shea D., O'Farrelly C., Exley M.A. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37:574-587.
68. Huh J.Y., Kim J.I., Park Y.J., Hwang I.J., Lee Y.S., Sohn J.H., Lee S.K., Alfadda A.A., Kim S.S., Choi S.H., Lee D.S., Park S.H., Seong R.H., Choi C.S., Kim J.B. A novel function of adipocytes in lipid antigen presentation to iNKT cells. Molecular Cell Biology 2013, 33:328-339.
69. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. American Journal of Cardiology 2006, 97:3A-11A.
70. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
71. Tse K., Tse H., Sidney J., Sette A., Ley K. T cells in atherosclerosis. International Immunology 2013, 25:615-622.
72. Grivel J.C., Ivanova O., Pinegina N., Blank P.S., Shpektor A., Margolis L.B., Vasilieva E. Activation of T lymphocytes in atherosclerotic plaques. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:2929-2937.
73. Braun N.A., Covarrubias R., Major A.S. Natural killer T cells and atherosclerosis: form and function meet pathogenesis. Journal of Innate Immunity 2010, 2:316-324.
74. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2:e779.
75. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., Merval R., Esposito B., Cohen J.L., Fisson S., Flavell R.A., Hansson G.K., Klatzmann D., Tedgui A., Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nature Medicine 2006, 12:178-180.
76. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:3893-3897.
77. Kol A., Sukhova G.K., Lichtman A.H., Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998, 98:300-307.
78. Kol A., Bourcier T., Lichtman A.H., Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. Journal of Clinical Investigation 1999, 103:571-577.
79. de Jager S.C., Kuiper J. Vaccination strategies in atherosclerosis. Thrombosis and Haemostasis 2011, 106:796-803.
80. van Puijvelde G.H., Hauer A.D., de V.P., van den Heuvel R., van Herwijnen M.J., van der Zee R., van E.W., van Berkel T.J., Kuiper J. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006, 114:1968-1976.
81. Hermansson A., Ketelhuth D.F., Strodthoff D., Wurm M., Hansson E.M., Nicoletti A., Paulsson-Berne G., Hansson G.K. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. Journal of Experimental Medicine 2010, 207:1081-1093.
82. Hermansson A., Johansson D.K., Ketelhuth D.F., Andersson J., Zhou X., Hansson G.K. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011, 123:1083-1091.
83. Herbin O., Ait-Oufella H., Yu W., Fredrikson G.N., Aubier B., Perez N., Barateau V., Nilsson J., Tedgui A., Mallat Z. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2012, 32:605-612.
84. Harats D., Yacov N., Gilburd B., Shoenfeld Y., George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. Journal of the American College of Cardiology 2002, 40:1333-1338.
85. Maron R., Sukhova G., Faria A.M., Hoffmann E., Mach F., Libby P., Weiner H.L. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002, 106:1708-1715.
86. Eckel R.H., Alberti K.G., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2010, 375:181-183.